NewsResearch pCODR Final Recommendation Issued for ibrutinib (Imbruvica) for Waldenstrom’s Macroglobulinemia
NewsResearch pCODR Final Recommendation Issued for ibrutinib (Imbruvica) for First-line Treatment of CLL
NewsResearch pCODR Final Recommendation Issued for ibrutinib (Imbruvica) for Mantle Cell Lymphoma (MCL)
NewsResearch Health Canada Approves Venetoclax for CLL Patients With 17P deletion or if No Other Treatment Options are Available
